Key points:
- Bristol Myers Squibb reports fourth quarter earnings
- EPS beats analyst expectations
- Revenue for the quarter misses expectations
- The Best Healthcare Stocks to Buy Right Now
Bristol Myers Squibb (NYSE: BMY) announced an earnings per share of $1.83 before the bell on Friday, with revenue coming in at $11.99 billion.
The numbers reported were against an anticipated EPS of $1.80 and revenue of $12.04 billion.
The company’s U.S. revenues increased 11% to $7.5 billion in the quarter, while international revenues increased 4% to $4.5 billion.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
Also Read: The Best Monthly Dividend Stocks Under $10
In reaction to the report, BMY’s share price has moved 0.5% to $64.40.
“2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio,” said Giovanni Caforio, CEO of Bristol Myers Squibb.
“I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib.”
The company sees full-year 2022 adjusted EPS between $7.65 and $7.95. BMY expects worldwide revenues to be approximately $47 billion, representing an increase in the low-single digits.